Technology Bundle ID
TAB-3495

Stable Pharmaceutical Formulation of Propofol Hemisuccinate for Inhalation Delivery

Applications
Linked ID
E-245-2015-0
Lead Inventors
Swayam Prabha (University of Minnesota)
Co-Inventors
Raj Suryanarayanan (University of Minnesota)
Seema Thakral (University of Minnesota)
Tanmoy Sadhukha (University of Minnesota)
Vadim Gurvich (University of Minnesota)
This technology includes a stable pharmaceutical formulation of propofol hemisuccinate for inhalation delivery to treat intractable epilepsy and migraine. The formulation can be used to treat a patient experiencing a seizure aura to prevent a motor seizure. Alternatively, the formulation can be used to treat an epileptic patient who is experiencing seizure clusters in an out-of-hospital or in-hospital setting. For migraines, the formulation can be used to treat a patient experiencing a migraine aura or early migraine to forestall the development of the full symptoms of a migraine headache.
Commercial Applications
Further clinical work could establish the formulation described in this technology for inhalation delivery to treat intractable epilepsy and migraine.
Competitive Advantages
The current formulation is the first available treatment optimized for inhalation delivery for the treatment of both epilepsy and migraine.

Request More Info

Licensing Contact: